Prognostic value of tumor microenvironment molecules in the response to immunotherapy in advanced melanoma

Prognostic value of tumor microenvironment molecules in the response to immunotherapy in advanced melanoma

Saved in:

Bibliographic Details
Main Authors:	L. Parra-Navarro, A. Calon, M. Iglesias-Coma, E. Andrades-López, A. Sallent-Aragay, C. Solé-Blanch, J. Vidal-Barrull, S. España-Fernández, A. Martínez-Cardús, R.M. Pujol, S. Segura
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001496
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Unraveling the Impact of Microbiome on Immunotherapy Efficacy in Melanoma
by: J. Bagué Companys, et al.
Published: (2024-01-01)

Benefit of immunotherapy for advanced melanoma in two patients with xeroderma pigmentosum
by: A.C. Rivas Segovia, et al.
Published: (2024-01-01)

Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy
by: M. Willemsen, et al.
Published: (2024-12-01)

Developing Costimulatory Molecules for Immunotherapy of Diseases /
by: Mir, Manzoor Ahmad
Published: (2015)

Dupilumab for the treatment of bullous pemphigoid triggered by melanoma immunotherapy
by: A. Tsentemeidou, et al.
Published: (2024-01-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

Tumor-infiltrating lymphocytes for melanoma immunotherapy
by: Oliver Kepp, et al.
Published: (2023-12-01)

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Immunotherapy of osteosarcoma based on immune microenvironment modulation
by: Heping Lian, et al.
Published: (2025-01-01)

Characteristics of Immunobiology in the Tumor Microenvironment- Development of Immunotherapies
by: Jian Song, et al.
Published: (2019-01-01)

Adjuvant lymph node radiotherapy and immunotherapy in stage III melanoma
by: L. Marxgut, et al.
Published: (2024-01-01)

Differences in expression profiles in malingant melanoma patients according to immunotherapy response
by: E. N. Lukyanova, et al.
Published: (2018-01-01)

Adjuvant and neoadjuvant immunotherapy for acral and mucosal melanoma
by: Takaya Komori, et al.
Published: (2025-01-01)

Advances in Immunotherapy for Melanoma: A Comprehensive Review
by: Carmen Rodríguez-Cerdeira, et al.
Published: (2017-01-01)

Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
by: Xue Wang, et al.
Published: (2025-01-01)

Tumor microenvironment and immunotherapy for triple-negative breast cancer
by: Zijie Guo, et al.
Published: (2024-12-01)

New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma
by: Cong Luo, et al.
Published: (2025-01-01)

Sex-specific and sex hormonal-related differences in melanoma microenvironment
by: Selene Attorre, et al.
Published: (2024-12-01)

Modulation of Acid Sphingomyelinase in Melanoma Reprogrammes the Tumour Immune Microenvironment
by: Emma Assi, et al.
Published: (2015-01-01)

K21-Antigen: A Molecule Shared by the Microenvironments of the Human Thymus and Germinal Centers
by: Nesrina Imami, et al.
Published: (1998-01-01)

Sex-specific difference for melanoma from immunotherapy advancement
by: Qianqian Li, et al.
Published: (2024-11-01)

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment
by: Eric A. Smith, et al.
Published: (2024-12-01)

Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing
by: Alice Perucca, et al.
Published: (2025-02-01)

Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy
by: Minni Zhang, et al.
Published: (2025-01-01)

Two-dimensional nano-biomaterials in regulating the tumor microenvironment for immunotherapy
by: Guangyu Xu, et al.
Published: (2024-12-01)

Angiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy
by: Taotao Yan, et al.
Published: (2024-12-01)

The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment
by: Delia Nelson, et al.
Published: (2014-01-01)

Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma
by: Lin Zhang, et al.
Published: (2025-01-01)

APAVAC Immunotherapy for the Adjuvant Treatment of a Canine Mucosal Melanoma
by: Valentina Rinaldi, et al.
Published: (2024-12-01)

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma
by: Hong Liu, et al.
Published: (2024-11-01)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
by: Massimo Ralli, et al.
Published: (2020-01-01)

Tumor microenvironment (TME) features and serum cytokines in patients with metastatic uveal and cutaneous melanoma treated with tebentafusp
by: O. Hamid, et al.
Published: (2024-01-01)

Revealing the structural microenvironment of high metastatic risk uveal melanomas following decellularisation
by: Karen Aughton, et al.
Published: (2024-11-01)

The interplay between persistent pathogen infections with tumor microenvironment and immunotherapy in cancer
by: Si Chen, et al.
Published: (2024-09-01)

Regulation of Oxygen in the Tumor Microenvironment Synergizes with Immunotherapy to Suppress Tumor Progression
by: Shoucheng Wang, et al.
Published: (2024-11-01)

Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment
by: Christian Klein, et al.
Published: (2025-01-01)

A Full GMP Process to Select and Amplify Epitope-Specific T Lymphocytes for Adoptive Immunotherapy of Metastatic Melanoma
by: N. Labarriere, et al.
Published: (2013-01-01)

Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
by: G. Lyrarakis, et al.
Published: (2024-01-01)

Sarcoidosis-Like Reaction in Melanoma Patients Receiving Immunotherapy or Targeted Therapy
by: Giulia Murgia, et al.
Published: (2024-01-01)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
by: Gérald E. Piérard, et al.
Published: (2012-01-01)